Robert Dubois, MD, PhD

Transformative therapies with high up-front costs will exacerbate the need to address gaps between payers when costs and benefits occur at different times.

This study found that brand price at launch and generic entry overstates long-run average pharmaceutical costs, with and without accounting for medical cost offsets.

Care pathways influence quality of care and outcomes. Despite positive trends in development and implementation, further efforts in process transparency and evaluation are required.